US Bancorp
ACAD icon

US Bancorp’s Acadia Pharmaceuticals ACAD Stock Holding History

US Bancorp’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.5K Sell
157
-72
-31% -$1.72K ﹤0.01% 3671
2025
Q4 		$6.12K Hold
229
– – ﹤0.01% 3469
2025
Q3 		$4.89K Sell
229
-16
-7% -$378 ﹤0.01% 3553
2025
Q2 		$5.29K Sell
245
-32,469
-99% -$604K ﹤0.01% 3618
2025
Q1 		$543K Sell
32,714
-144
-0.4% -$2.62K ﹤0.01% 1427
2024
Q4 		$603K Sell
32,858
-76
-0.2% -$1.23K ﹤0.01% 1396
2024
Q3 		$507K Buy
32,934
+31,426
+2,084% +$524K ﹤0.01% 1519
2024
Q2 		$24.5K Buy
1,508
+848
+128% +$13.7K ﹤0.01% 2980
2024
Q1 		$12.2K Sell
660
-1
-0.2% -$25 ﹤0.01% 3267
2023
Q4 		$20.7K Sell
661
-43
-6% -$1.03K ﹤0.01% 3034
2023
Q3 		$14.7K Sell
704
-1
-0.1% -$27 ﹤0.01% 3013
2023
Q2 		$16.9K Sell
705
-605
-46% -$13.4K ﹤0.01% 3058
2023
Q1 		$24.7K Buy
1,310
+299
+30% +$5.7K ﹤0.01% 2881
2022
Q4 		$16.1K Sell
1,011
-216
-18% -$3.38K ﹤0.01% 3104
2022
Q3 		$20K Sell
1,227
-314
-20% -$5.08K ﹤0.01% 3006
2022
Q2 		$22K Sell
1,541
-1,481
-49% -$27.6K ﹤0.01% 2987
2022
Q1 		$73K Buy
3,022
+575
+23% +$13.9K ﹤0.01% 2424
2021
Q4 		$57K Sell
2,447
-1,691
-41% -$34K ﹤0.01% 2578
2021
Q3 		$69K Sell
4,138
-415
-9% -$8K ﹤0.01% 2485
2021
Q2 		$111K Buy
4,553
+569
+14% +$12.8K ﹤0.01% 2258
2021
Q1 		$103K Buy
3,984
+181
+5% +$7.97K ﹤0.01% 2257
2020
Q4 		$202K Sell
3,803
-1,051
-22% -$52.2K ﹤0.01% 1869
2020
Q3 		$200K Buy
4,854
+50
+1% +$2.16K ﹤0.01% 1769
2020
Q2 		$233K Sell
4,804
-734
-13% -$35.2K ﹤0.01% 1670
2020
Q1 		$234K Buy
5,538
+1,818
+49% +$74.9K ﹤0.01% 1580
2019
Q4 		$159K Buy
3,720
+2,374
+176% +$103K ﹤0.01% 1952
2019
Q3 		$48K Buy
1,346
+868
+182% +$26.3K ﹤0.01% 2484
2019
Q2 		$12K Sell
478
-594
-55% -$15.2K ﹤0.01% 3033
2019
Q1 		$28K Sell
1,072
-532
-33% -$12.4K ﹤0.01% 2724
2018
Q4 		$26K Sell
1,604
-62
-4% -$1.2K ﹤0.01% 2707
2018
Q3 		$35K Buy
1,666
+1,590
+2,092% +$25K ﹤0.01% 2719
2018
Q2 		$1K Sell
76
-399
-84% -$7.11K ﹤0.01% 3531
2018
Q1 		$11K Sell
475
-995
-68% -$27.5K ﹤0.01% 3115
2017
Q4 		$44K Sell
1,470
-223
-13% -$7.13K ﹤0.01% 2652
2017
Q3 		$63K Buy
1,693
+690
+69% +$22.4K ﹤0.01% 2458
2017
Q2 		$28K Buy
1,003
+637
+174% +$19K ﹤0.01% 2769
2017
Q1 		$13K Buy
366
+48
+15% +$1.69K ﹤0.01% 2958
2016
Q4 		$9K Buy
318
+218
+218% +$5.77K ﹤0.01% 3040
2016
Q3 		$3K Hold
100
– – ﹤0.01% 3246
2016
Q2 		$3K Hold
100
– – ﹤0.01% 3275
2016
Q1 		$3K Sell
100
-1,393
-93% -$30.4K ﹤0.01% 3264
2015
Q4 		$53K Sell
1,493
-402
-21% -$14.2K ﹤0.01% 2413
2015
Q3 		$63K Buy
1,895
+320
+20% +$13.3K ﹤0.01% 2333
2015
Q2 		$66K Buy
1,575
+1,311
+497% +$50.7K ﹤0.01% 2375
2015
Q1 		$9K Hold
264
– – ﹤0.01% 3146
2014
Q4 		$8K Buy
+264
New +$7.49K ﹤0.01% 3161
2014
Q2 		– Sell
-1,575
Closed -$39K – 3479
2014
Q1 		$39K Buy
1,575
+27
+2% +$683 ﹤0.01% 2581
2013
Q4 		$39K Buy
+1,548
New +$36.5K ﹤0.01% 2517

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

US Bancorp's ACAD Position: Q1 2026 in Review

US Bancorp reduced its Acadia Pharmaceuticals (ACAD) stake by 31% in Q1 2026, selling an estimated $1.72K and leaving 157 shares worth $3.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3671.

US Bancorp first reported a position in ACAD in Q4 2013 and has held it in 48 quarters since. The position peaked at $603K in Q4 2024. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • US Bancorp held 157 shares of Acadia Pharmaceuticals worth $3.5K as of Q1 2026.
  • US Bancorp sold 72 Acadia Pharmaceuticals shares in Q1 2026, an estimated $1.72K.
  • Acadia Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3671 holding.
  • US Bancorp first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 48 quarters since.
  • US Bancorp's Acadia Pharmaceuticals position peaked at $603K in Q4 2024.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.